Table of Contents Author Guidelines Submit a Manuscript
Cholesterol
Volume 2017 (2017), Article ID 5046294, 9 pages
https://doi.org/10.1155/2017/5046294
Review Article

The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies

Institute for Clinical Chemistry and Clinical Pharmacology, University Clinics of Bonn, Bonn, Germany

Correspondence should be addressed to Dieter Lütjohann; ed.nnob-inu.bku@nnahojteul.reteid

Received 16 September 2016; Revised 21 December 2016; Accepted 26 January 2017; Published 22 February 2017

Academic Editor: Akihiro Inazu

Copyright © 2017 Frans Stellaard and Dieter Lütjohann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Sudhop, M. Reber, D. Tribble et al., “Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men,” Journal of Lipid Research, vol. 50, no. 10, pp. 2117–2123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Sudhop, D. Lütjohann, A. Kodal et al., “Inhibition of intestinal cholesterol absorption by ezetimibe in humans,” Circulation, vol. 106, no. 15, pp. 1943–1948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Stellaard, K. von Bergmann, T. Sudhop, and D. Lütjohann, “The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies,” Journal of Steroid Biochemistry and Molecular Biology, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Clarenbach, M. Reber, D. Lütjohann, K. Von Bergmann, and T. Sudhop, “The lipid-lowering effect of ezetimibe in pure vegetarians,” Journal of Lipid Research, vol. 47, no. 12, pp. 2820–2824, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. E. Telford, B. G. Sutherland, J. Y. Edwards, J. D. Andrews, P. H. R. Barrett, and M. W. Huff, “The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin,” Journal of Lipid Research, vol. 48, no. 3, pp. 699–708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Schonewille, J. F. De Boer, L. Mele et al., “Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice,” Journal of Lipid Research, vol. 57, no. 8, pp. 1455–1464, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Grundy and E. H. Ahrens Jr., “Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods,” Journal of Lipid Research, vol. 10, no. 1, pp. 91–107, 1969. View at Google Scholar · View at Scopus
  8. D. S. Goodman, R. P. Noble, and R. B. Dell, “Three-pool model of the long-term turnover of plasma cholesterol in man,” Journal of Lipid Research, vol. 14, no. 2, pp. 178–188, 1973. View at Google Scholar · View at Scopus
  9. E. R. Smith, R. B. Dell, R. P. Noble, and D. S. Goodman, “Parameters of the three-pool model of the turnover of plasma cholesterol in normal and hyperlipidemic humans,” The Journal of Clinical Investigation, vol. 57, no. 1, pp. 137–148, 1976. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Goodman, F. R. Smith, A. H. Seplowitz, R. Ramakrishnan, and R. B. Dell, “Prediction of the parameters of whole body cholesterol metabolism in humans,” Journal of Lipid Research, vol. 21, no. 6, pp. 699–713, 1980. View at Google Scholar · View at Scopus
  11. J. R. Crouse and S. M. Grundy, “Evaluation of a continuous isotope feeding method for measurement of cholesterol absorption in man,” Journal of Lipid Research, vol. 19, no. 8, pp. 967–971, 1978. View at Google Scholar · View at Scopus
  12. D. Lutjohann, C. O. Meese, J. R. Crouse III, and K. Von Bergmann, “Evaluation of deuterated cholesterol and deuterated sitostanol for measurement of cholesterol absorption in humans,” Journal of Lipid Research, vol. 34, no. 6, pp. 1039–1046, 1993. View at Google Scholar · View at Scopus
  13. M. S. Bosner, R. E. Ostlund Jr., O. Osofisan, J. Grosklos, C. Fritschle, and L. G. Lange, “Assessment of percent cholesterol absorption in humans with stable isotopes,” Journal of Lipid Research, vol. 34, no. 6, pp. 1047–1053, 1993. View at Google Scholar · View at Scopus
  14. A. E. Van Der Velde, G. Brufau, and A. K. Groen, “Transintestinal cholesterol efflux,” Current Opinion in Lipidology, vol. 21, no. 3, pp. 167–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Van Der Velde, C. L. J. Vrins, K. Van Den Oever et al., “Regulation of direct transintestinal cholesterol excretion in mice,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 295, no. 1, pp. G203–G208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. U. J. F. Tietge and A. K. Groen, “Role the TICE? advancing the concept of transintestinal cholesterol excretion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 7, pp. 1452–1453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Dietschy, D. K. Spady, and E. F. Stange, “Quantitative important of different organs for cholesterol synthesis and low-density-lipoprotein degradation,” Biochemical Society Transactions, vol. 11, no. 6, pp. 639–641, 1983. View at Publisher · View at Google Scholar · View at Scopus
  18. D. K. Spady and J. M. Dietschy, “Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat,” Journal of Lipid Research, vol. 24, no. 3, pp. 303–315, 1983. View at Google Scholar · View at Scopus
  19. S. D. Turley, D. K. Spady, and J. M. Dietschy, “Role of liver in the synthesis of cholesterol and the clearance of low density lipoproteins in the cynomolgus monkey,” Journal of Lipid Research, vol. 36, no. 1, pp. 67–79, 1995. View at Google Scholar · View at Scopus
  20. J. M. Dietschy, S. D. Turley, and D. K. Spady, “Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans,” Journal of Lipid Research, vol. 34, no. 10, pp. 1637–1659, 1993. View at Google Scholar · View at Scopus
  21. D. J. Jeske and J. M. Dietschy, “Regulation of rates of cholesterol synthesis in vivo in the liver and carcass of the rat measured using [3H]water,” Journal of Lipid Research, vol. 21, no. 3, pp. 364–376, 1980. View at Google Scholar · View at Scopus
  22. L. J. Engelking, M. R. McFarlane, C. K. Li, and G. Liang, “Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes,” Journal of Lipid Research, vol. 53, no. 7, pp. 1359–1368, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Nakano, I. Inoue, Y. Takenaka et al., “Ezetimibe promotes brush border membrane-to-lumen cholesterol efflux in the small intestine,” PLoS ONE, vol. 11, no. 3, Article ID e0152207, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Uto-Kondo, M. Ayaori, G. M. Sotherden et al., “Ezetimibe enhances macrophage reverse cholesterol transport in hamsters: contribution of hepato-biliary pathway,” Biochimica et Biophysica Acta, vol. 1841, no. 9, pp. 1247–1255, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Davidson, J. Voogt, J. Luchoomun et al., “Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans,” Atherosclerosis, vol. 230, no. 2, pp. 322–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Hellerstein and S. Turner, “Reverse cholesterol transport fluxes,” Current Opinion in Lipidology, vol. 25, no. 1, pp. 40–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Tremblay, B. Lamarche, J. S. Cohn, J.-C. Hogue, and P. Couture, “Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 1101–1106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Tremblay, B. Lamarche, J.-C. Hogue, and P. Couture, “Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia,” Journal of Lipid Research, vol. 50, no. 7, pp. 1463–1471, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. C. Chan, G. F. Watts, S. K. Gan, E. M. M. Ooi, and P. H. R. Barrett, “Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet,” Diabetes Care, vol. 33, no. 5, pp. 1134–1139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. H. H. Wang, P. Portincasa, N. Mendez-Sanchez, M. Uribe, and D. Q.-H. Wang, “Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones,” Gastroenterology, vol. 134, no. 7, pp. 2101–2110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Portincasa and D. Q.-H. Wang, “Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation?” Hepatology, vol. 55, no. 5, pp. 1313–1316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Mazzella, A. Cipolla, N. Villanova et al., “Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects,” Italian Journal of Gastroenterology, vol. 27, no. 8, pp. 441–445, 1995. View at Google Scholar · View at Scopus
  33. P. Loria, M. Bertolotti, M. T. Cassinadri et al., “Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects,” Hepatology, vol. 19, no. 4, pp. 882–888, 1994. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Mazzella, P. Parini, D. Festi et al., “Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia,” Hepatology, vol. 15, no. 6, pp. 1072–1078, 1992. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Sasaki, T. Otonari, Y. Sawayama et al., “Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin—effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in japanese patients with hypercholesterolemia (PEAS study),” Journal of Atherosclerosis and Thrombosis, vol. 19, no. 5, pp. 485–493, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. O. S. Descamps, J. De Sutter, M. Guillaume, and L. Missault, “Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?” Atherosclerosis, vol. 217, no. 2, pp. 308–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Bjorkhem, T. Miettinen, E. Reihner, S. Ewerth, B. Angelin, and K. Einarsson, “Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver,” Journal of Lipid Research, vol. 28, no. 10, pp. 1137–1143, 1987. View at Google Scholar · View at Scopus
  38. K. Nikkilä, M. J. Nissinen, H. Gylling, H. Isoniemi, and T. A. Miettinen, “Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation,” Journal of Hepatology, vol. 49, no. 6, pp. 936–945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Nikkilä, T. A. Miettinen, K. V. A. Höckerstedt, and H. Isoniemi, “Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation,” Transplant International, vol. 18, no. 2, pp. 221–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Nikkilä, K. Höckerstedt, and T. A. Miettinen, “Liver transplantation modifies serum cholestanol, cholesterol precursor and plant sterol levels,” Clinica Chimica Acta, vol. 208, no. 3, pp. 205–218, 1992. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Lindenthal, T. A. Aldaghlas, A. L. Holleran et al., “Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells,” American Journal of Physiology—Endocrinology and Metabolism, vol. 282, no. 6, pp. E1222–E1230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Niemi, P. J. Neuvonen, U. Hofmann et al., “Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype 17,” Pharmacogenetics and Genomics, vol. 15, no. 5, pp. 303–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Mitsche, J. G. McDonald, H. H. Hobbs, and J. C. Cohen, “Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways,” eLife, vol. 4, Article ID e07999, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Mathur, J. J. Walker, H. H. Al-Azzawi et al., “Ezetimibe ameliorates cholecystosteatosis,” Surgery, vol. 142, no. 2, pp. 228–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Ezzet, G. Krishna, D. B. Wexler, P. Statkevich, T. Kosoglou, and V. K. Batra, “A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe,” Clinical Therapeutics, vol. 23, no. 6, pp. 871–885, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-W. Bae, C.-I. Choi, J.-H. Lee, C.-G. Jang, M.-W. Chung, and S.-Y. Lee, “Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects,” European Journal of Clinical Pharmacology, vol. 67, no. 1, pp. 39–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. P. P. Toth and M. H. Davidson, “Cholesterol absorption blockade with ezetimibe,” Current Drug Targets—Cardiovascular and Haematological Disorders, vol. 5, no. 6, pp. 455–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S.-W. Park, “Intestinal and hepatic niemann-pick c1-like 1,” Diabetes and Metabolism Journal, vol. 37, no. 4, pp. 240–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. R. E. Temel, W. Tang, Y. Ma et al., “Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe,” Journal of Clinical Investigation, vol. 117, no. 7, pp. 1968–1978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Petruzzelli and A. Moschetta, “Hepatic Niemann-Pick C1-like 1: the canalicular side of the coin,” Hepatology, vol. 46, no. 6, pp. 2040–2042, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Yamamura, Y. Ohsaki, M. Suzuki et al., “Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant α1-antitrypsin Z deposition,” Hepatology, vol. 59, no. 4, pp. 1591–1599, 2014. View at Publisher · View at Google Scholar · View at Scopus